PAION AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]
August 02, 2017 at 07:00 am EDT
Share
DGAP Preliminary announcement financial reports: PAION AG / Preliminary announcement on the disclosure of financial statements
PAION AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]
02.08.2017 / 13:00
Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
PAION AG hereby announces that the following financial reports shall be
disclosed :
Report: Financial report of the group (half-year/Q2)
Date of disclosure / German: August 09, 2017
Date of disclosure / English: August 09, 2017
German: http://www.paion.com/de/medien-und-investoren/investorcenter/finanzberichte/
English: http://www.paion.com/media-and-investors/investorcenter/financial-reports/
02.08.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.